Sector Update: Health Care Stocks Decline Late Afternoon

Published on 2025-03-10 at 15:58 - Modified on 2025-03-10 at 16:03

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

Earnings, inflation data confront resilient US stocks rally	07-13	RE
S&P 500 ends down as tariffs sour sentiment	07-11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
HSBC Adjusts Johnson & Johnson's Price Target to $180 From $184, Keeps Buy Rating	07-11	MT
Wall St Week Ahead-Earnings, inflation data confront resilient US stocks rally	07-11	RE
Morgan Stanley Adjusts PT on Johnson & Johnson to $171 From $169, Maintains Equalweight Rating	07-10	MT
Jabil Inc. : Investing to stay ahead	07-10
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
Transgene SA Announces Board Changes	07-09	CI
Johnson & Johnson's Q2 Earnings Call Likely to Focus on Guidance, Tariff Impact, BofA Says	07-09	MT
Company earnings: key dates for next week	07-09
Trump says pharmaceutical tariffs could reach 200%	07-08	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	07-08	MT
Volatility as a Strategy	07-08
J&J: seeks FDA approval for Caplyta for schizophrenia	07-08
Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia	07-08	CI
Johnson & Johnson Submits Supplemental NDA for Schizophrenia Treatment Caplyta	07-08	MT
Nanobiotix: NBTXR3 device reclassified as a drug	07-08
Nanobiotix Reports Regulatory Harmonization, New Composition of Matter Patent Filed for JNJ-1900	07-07	MT
Johnson & Johnson Unit Submits EMA Application to Extend Indication of Akeega for Prostate Cancer	07-03	MT
J&J Unit Seeks Indication Extension for Cancer Drug Combo in EU	07-03	MT
US FDA approves Regeneron's blood cancer therapy	07-02	RE